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Objective. To investigate the association of
NLRP3, NOD2, MEFV, and PSTPIP1, genes that cause 4
of the autoinflammatory hereditary periodic fever syn-
dromes (HPFS), with juvenile idiopathic arthritis (JIA).
Methods. Fifty-one single-nucleotide polymor-
phisms (SNPs) across the 4 loci were investigated using
MassArray genotyping in 950 Caucasian patients with
JIA living in the UK and 728 ethnically matched healthy
controls.
Results. Prior to Bonferroni correction for multi-
ple testing, significant genotype associations between 6
SNPs in MEFV and JIA were observed and, in subgroup
analysis, associations between 12 SNPs across all 4 loci
and the subgroup of patients with psoriatic JIA were
found. After Bonferroni correction for multiple testing,
2 genotype associations remained significant in the
subgroup of patients with psoriatic JIA (MEFV SNP
rs224204 [corrected P  0.025] and NLRP3 SNP
rs3806265 [corrected P  0.04]).
Conclusion. These findings support the use of
monogenic loci as candidates for investigating the ge-
netic component of complex disease and provide prelim-
inary evidence of association between SNPs in autoin-
flammatory genes and psoriatic JIA. Our findings raise
the interesting possibility of a shared disease mecha-
nism between the HPFS and psoriatic JIA, potentially
involving abnormal production of interleukin-1.
Juvenile idiopathic arthritis (JIA) is the most
common rheumatic disease of childhood. It is character-
ized by chronic inflammation of one or more synovial
joints, with onset before the age of 16 years and dura-
tion of 6 weeks (1). One approach to the selection of
JIA candidate genes is to use genes responsible for
monogenic syndromes that have an overlap of pheno-
type with JIA. This has been successful previously,
with the genes WISP3 and SLC26A2 shown to confer
susceptibility to specific subgroups of JIA (2,3). Con-
tinuing this strategy, we investigated the following
genes, which are responsible for 4 of the autoinflamma-
tory hereditary periodic fever syndromes (HPFS):
NLRP3 (CIAS1/cryopyrin/NALP3/PYPAF1), responsible
for cryopyrin-associated periodic syndrome; NOD2
(CARD15), responsible for Blau syndrome; MEFV
(marenostrin/pyrin), responsible for familial Mediterra-
nean fever; and PSTPIP1 (CD2BP1/PSTPIP), responsi-
ble for pyogenic arthritis, pyoderma gangrenosum, and
acne (PAPA) syndrome (4). The HPFS are a group of
monogenic autoinflammatory syndromes, unified by a
central phenotype of recurrent inflammation, often
manifested as unexplained fever, coupled with other
signs of systemic infection. Arthralgia or arthritis is often
present (4).
Certain characteristics are common to both
HPFS and JIA, especially systemic-onset JIA. These
include shared clinical features related to systemic in-
flammation, and a shared response to treatment with
interleukin-1 receptor antagonist (IL-1Ra) (anakinra),
suggesting a similar pathogenesis. In addition, poly-
morphisms in NALP1, a gene related to the HPFS gene
NLRP3, were recently shown to confer susceptibility to
vitiligo-associated autoimmune disease (5). This is rele-
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2142vant because the pathogenesis of JIA includes a substan-
tial autoimmune element. It was our hypothesis that
while severe mutations in the above genes will cause the
respective monogenic syndrome, milder genetic changes
(e.g., single-nucleotide polymorphisms [SNPs]) may give
rise to a more subtly altered protein, and hence contrib-
ute to the oligogenetic basis of JIA.
PATIENTS AND METHODS
Patients and controls. Blood samples were obtained
after subjects gave informed consent. Ethics approval was
obtained from the Multi-centre Research Ethics Committee
(MREC 99/8/84) and the University of Manchester Committee
on the Ethics of Research on Human Beings (8/92/[i] [b]).
Patients were classified according to the International League
of Associations for Rheumatology criteria (1).
DNA samples obtained from 950 patients with JIA
were available for genotyping of NLRP3, NOD2, and MEFV.
Of the 950 patients, 175 had systemic-onset JIA, 219 had
persistent oligoarticular JIA, 152 had extended oligoarticular
JIA, 185 had rheumatoid factor (RF)–negative polyarticular
JIA, 65 had RF-positive polyarticular JIA, 79 had enthesitis-
related JIA, 67 had psoriatic JIA, and 8 had unclassifiable JIA.
Samples obtained from 831 patients with JIA were available
for genotyping PSTPIP1. Of these patients, 133 had systemic-
onset JIA, 215 had persistent oligoarticular JIA, 127 had ex-
tended oligoarticular JIA, 168 had RF-negative polyarticular
JIA, 48 had RF-positive polyarticular JIA, 58 had enthesitis-
related JIA, 57 had psoriatic JIA, and 25 had unclassifiable
JIA. In addition, 728 unrelated, ethnically matched healthy
controls were genotyped for NLRP3, NOD2, and MEFV, and
628 for PSTPIP1. Controls were blood donors from the Oxford
region, subjects selected from the registries of general practi-
tioners in Norfolk, or members of a cohort of population-based
controls collected in the northwest region of England.
SNP selection. Pairwise haplotype-tagging SNPs were
selected for each gene using HapMap (www.hapmap.org) and
the tagger function in Haploview, version 3.32 software. This
panel was enriched with SNPs in functional domains (www.
ncbi.nih.gov/SNP; http://fmf.igh.cnrs.fr/ISSAID/infevers).
Genotyping. Fifty-one SNPs (21 in NLRP3, 13 in
NOD2,1 1i nMEFV,a n d6i nPSTPIP1) were genotyped by
MassArray DNA analysis. Amplifications were conducted ac-
cording to the recommendations of the manufacturer (Seque-
nom, San Diego, CA).
Statistical analysis. Prior to analysis, data for DNA
samples that failed to genotype in 50% of the SNPs assayed
and data for SNPs that failed to genotype in 10% of the
samples were removed. Hardy-Weinberg equilibrium was de-
termined separately for patients and controls using Stata,
version 9 (StataCorp, College Station, TX). SNPs were ex-
cluded from further analysis if deviation from Hardy-Weinberg
equilibrium (P  0.05) was observed in the controls.
Single-point analysis. Remaining SNPs were analyzed
by the chi-square test (or Fisher’s exact test when n  5), using
Stata, version 9. Genotype and allele associations, models of
dominant and recessive traits, and trend tests were investi-
gated. Exploratory uncorrected P (Puncorr) values are pre-
sented in Tables 1 and 2 and Supplementary Table 1 (available
on the Arthritis & Rheumatism Web site at http://www.mrw.
interscience.wiley.com/suppmat/0004-3591/suppmat/). Puncorr
values of less than or equal to 0.05 were considered to be
preliminary evidence of association. Initially, the entire group
of JIA patients was compared with controls, and then each
subgroup of JIA patients was compared with controls.
Wellcome Trust Case Control Consortium data. Geno-
type data from a study of 500,000 SNPs across the genome
have recently been made publicly available (6). For SNPs
(or perfect proxies, i.e., SNPs correlated with a correlation
coefficient of 1 [r
2  1]) that were included in both the
Wellcome Trust Case Control Consortium study and our
study, genotype frequencies from the control cohort of 3,000
individuals were compared with our control cohort using the
chi-square test. If statistically similar, the 2 cohorts were
merged and genotype frequencies were compared with the JIA
patients in the present study, both as a whole and by individual
subgroup.
Correction for multiple testing. Bonferroni correction
was performed, based on the 36 SNPs presented that passed
quality control criteria.
Multipoint analysis. Linkage disequilibrium was cal-
culated using Haploview, version 3.32. Evaluation of associa-
tion of haplotypes was carried out using a 2-marker sliding
window approach, implemented using Plink, version 0.99r.
Since MEFV and PSTPIP1 protein products are known to
interact (7), epistasis analysis, or analysis of evidence of gene–
gene interaction, was conducted using Plink, version 0.99r.
Power calculations. Power calculations for the study
were carried out using Quanto software (http://hydro.usc.edu/
GxE). Based on the smallest cohort sizes (831 patients and 628
controls), the study had 84% power to detect an odds ratio
(OR) of 1.4 at the 5% significance level. Using the Wellcome
Trust Case Control Consortium control genotype data for
3,000 additional controls (as described below) and our entire
JIA cohort (n  950), the study had 81% power to detect an
OR of 1.3.
RESULTS
Fifty-one SNPs were genotyped across the 4 loci.
Fifteen SNPs were excluded from further analysis, due
to either complete genotyping failure (rs10925015,
rs7525979, rs3135500), having a minor allele frequency
of 1% (rs2066844, despite the published HapMap
minor allele frequency of 0.22), deviating from Hardy-
Weinberg equilibrium in controls (rs4925659,
rs10925027, rs2066843, rs224234, rs2741918, rs224207,
rs224208, rs3935339), or falling below the required 90%
SNP genotyping success rate (rs4612666, rs10159239,
rs10754558).
Genotype frequencies of the remaining SNPs
were compared between JIA patients and controls.
Puncorr values showed preliminary evidence of associa-
tion between JIA and 6 SNPs, all of which were in the
MEFV gene (Table 1). However, following correction
AUTOINFLAMMATORY GENES AND PSORIATIC JIA 2143for multiple testing, no significant associations were
observed.
Similarly, prior to correction for multiple testing,
significant associations between 12 SNPs across all 4
loci and psoriatic JIA were observed (Supplementary
Table 1). In addition, an association between SNP
Table 1. Genotype frequencies of MEFV SNPs in JIA patients and controls*
SNP
JIA patients Controls
P‡ Sample size P† Genotype frequency Sample size P† Genotype frequency
rs2741919 782 0.43 723 0.07 0.042
TT 239 (30.6) 263 (36.4)
TC 397 (50.8) 326 (45.1)
CC 146 (18.7) 134 (18.5)
rs224204 783 0.06 721 0.06 0.005
TT 178 (22.7) 213 (29.5)
TC 418 (53.4) 334 (46.3)
CC 187 (23.9) 174 (24.1)
rs224213 770 0.71 722 0.16 0.143
TT 248 (32.2) 267 (37.0)
TC 383 (49.7) 329 (45.6)
CC 139 (18.1) 126 (17.5)
rs224215 714 0.12 699 0.43 0.028
TT 280 (39.2) 257 (36.8)
TC 350 (49.0) 325 (46.5)
CC 84 (11.8) 117 (16.7)
rs224217 772 0.34 719 0.10 0.008
TT 227 (29.4) 195 (27.1)
TC 396 (51.3) 337 (46.9)
CC 149 (19.3) 187 (26.0)
rs224223 709 0.88 691 0.20 0.043
CC 207 (29.2) 181 (26.2)
CA 355 (50.1) 328 (47.5)
AA 147 (20.7) 182 (26.3)
rs224225 777 0.52 722 0.10 0.014
TT 230 (29.6) 195 (27.0)
TC 394 (50.7) 339 (47.0)
CC 153 (19.7) 188 (26.0)
* Except where indicated otherwise, values are the number (%). SNPs  single-nucleotide polymor-
phisms; JIA  juvenile idiopathic arthritis.
† For Hardy-Weinberg equilibrium.
‡ Uncorrected P value for genotype association.
Table 2. Genotype association results obtained using genotype data from the present study only and from both the present study and the Wellcome






P for all JIA† P for psoriatic JIA‡
Data from present
study only All data
Data from present
study only All data
NLRP3/rs10754555 696 3,627 0.666 0.794 0.133 0.205
NOD2/rs1861759 715 3,648 0.309 0.05 0.031 0.009
NOD2/rs751271 724 3,523 0.239 0.259 0.053 0.075
NOD2/rs313499 723 3,634 0.212 0.023 0.084 0.069
PSTPIP1/rs2254441§ 551 3,446 0.539 0.109 0.016 0.006
* Genotype data (n  3,000) from the Wellcome Trust Case Control Consortium were merged with the control cohort data from the present study,
after comparing the 2 cohorts using the chi-square test to ensure that they were statistically similar.
† Uncorrected P value for all patients with juvenile idiopathic arthritis (JIA) versus controls. P values of less than or equal to 0.05 were considered
significant.
‡ Uncorrected P value for patients with psoriatic JIA versus controls. P values of less than or equal to 0.05 were considered significant.
§ A perfect proxy single-nucleotide polymorphism (SNP) for rs2254441 (rs1022197; r
2  1) was found in the Wellcome Trust Case Control
Consortium data.
2144 DAY ET ALrs4078354 in PSTPIP1 and systemic-onset JIA was ob-
served (Puncorr  0.026). Associations were also observed
between persistent oligoarticular JIA and rs224225 in
MEFV (Puncorr  0.022) and rs224217 in MEFV
(Puncorr  0.031), between extended oligoarticular JIA
and rs224217 in MEFV (Puncorr  0.047), and between
RF-negative polyarticular JIA and rs224215 in MEFV
(Puncorr  0.009).
After applying the stringent Bonferroni correc-
tion for multiple testing, 2 SNPs, rs224204 in MEFV and
rs3806265 in NLRP3, remained significantly associated
by genotype. Both were associated with psoriatic JIA
(corrected P  0.025 for rs224204 and corrected P 
0.04 for rs3806265).
Haplotype association analysis was carried out
for SNPs in all loci, but no haplotype association of an
order of magnitude greater than the single-point associ-
ation was observed. Also, no significant epistatic inter-
action between MEFV and PSTPIP1 was found.
Four SNPs from our study were also included in
the Wellcome Trust Case Control Consortium study,
and 1 SNP was covered by a perfect proxy SNP (r
2  1),
with genotype frequencies that were not statistically
significantly different between the 2 control cohorts
(Table 2). Control genotype data were therefore merged
and compared with the JIA patient data, both as a
whole and by individual subgroup. Two SNPs (rs1861759
and rs313499), both in NOD2, which were previously not
significantly associated with JIA, were then found to be
significantly associated with JIA overall (Puncorr 
0.05 and Puncorr  0.023, respectively). For 1 of these
SNPs (rs1861759), and for the SNP covered by the
perfect proxy (rs2254441 in PSTPIP1), the previously
observed association with psoriatic JIA was maintained
with an increased significance level (Puncorr  0.009 and
Puncorr  0.006, respectively) (Table 2).
DISCUSSION
NLRP3, NOD2, MEFV, and PSTPIP1 are the
genes responsible for 4 of the syndromes collectively
termed hereditary periodic fever syndromes (HPFS) (4).
These are autoinflammatory, monogenic syndromes,
characterized by recurrent and seemingly unprovoked
episodes of inflammation and fever (8). Because of the
overlap between these conditions and JIA, specifically
systemic-onset JIA, we hypothesized that SNPs within
these genes may confer susceptibility to JIA. However,
rather than finding associations with systemic-onset JIA,
we unexpectedly observed associations with psoriatic JIA.
We increased the size of our control cohort by
using genotype data from the Wellcome Trust Case
Control Consortium (6). By increasing the power of the
study in this way, we uncovered additional associations
between SNPs in NOD2 and JIA, although these were
not significant once Bonferroni correction for multiple
testing was applied.
The 4 genes that were studied all encode for
proteins that are fundamental components of the innate
immune system (4). These proteins are thought to
contribute to an intracellular pathogen-sensing mecha-
nism, the output of which is increased production and
secretion of IL-1, via activation of caspase 1 (4).
The IL-1 family has been shown to play an
important role in the pathogenesis of psoriasis. Overex-
pression of IL-1 in basal epidermis in transgenic mice
initiates a psoriasis-like cutaneous inflammation (9).
Moreover, deletion of the IL-1Ra gene in transgenic
mice has been shown to induce psoriasiform cutaneous
inflammation (10).
It is possible that polymorphisms in the genes
investigated in this study may have downstream effects
on IL-1 production and processing, and subsequently
affect susceptibility to psoriatic JIA. IL-1Ra (anakinra)
is used as an effective treatment for both HPFS and
systemic-onset JIA. If our data are replicated in addi-
tional studies, it is possible that treatment with IL-1
antagonists could be extended to psoriatic JIA, as a
novel and potentially effective treatment.
Two of the genes used in this study have previ-
ously been shown to be associated with complex auto-
immune diseases other than JIA. NOD2 confers suscep-
tibility to Crohn’s disease (11). NOD2 controls both
innate and adaptive immune responses, through the
regulation of cytokines, chemokines, and antimicrobial
peptide production. The mechanism by which genetic
variation in NOD2 confers disease susceptibility has yet
to be fully elucidated (12). It has been suggested that
MEFV is a predisposing factor for Behc ¸et’s disease (13).
Furthermore, mutations within MEFV have previously
been described in both juvenile and adult inflammatory
arthritis (14,15). Also, NALP1, a homolog of NLRP3,
has recently been shown to be associated with vitiligo-
associated multiple autoimmune disease (5).
Although JIA is the most common chronic rheu-
matic disease of childhood, it is a rare condition, affect-
ing only 1 in 10,000 children under the age of 16 years.
While our total JIA cohort is quite large, numbers in any
one subgroup are relatively small. Additional support for
these findings is required, in the form of replication
cohorts and functional studies.
The SNPs rs4078354 and rs8030698 within
AUTOINFLAMMATORY GENES AND PSORIATIC JIA 2145PSTPIP1 have been studied in a discovery cohort of
psoriatic JIA patients from Texas. No significant trends
were seen (Wise C: personal communication). However,
the sample size in that cohort was too small to ade-
quately test replication, and further study in a larger
cohort is still required in order to confirm or refute our
findings.
In summary, we studied a large group of Cauca-
sian JIA patients living in the UK and ethnically
matched healthy controls and found preliminary evi-
dence of association of NLRP3, NOD2, MEFV, and
PSTPIP1 with psoriatic JIA. These findings support the
value of extrapolating from monogenic syndromes to
identify candidate susceptibility genes for complex dis-
ease. Further studies, in different populations of psori-
atic JIA patients, should be performed to replicate these
findings.
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